PROTOX ANNOUNCES DETAILS OF 2011 ANNUAL SHAREHOLDER MEETING

- Provides Non-mail Options for Proxy Voting -

SAN DIEGO AND VANCOUVER, June 6, 2011 /CNW/ - Protox Therapeutics Inc. (the "Company" or "Protox") (TSX: PRX), a leader in the development of receptor targeted therapeutic fusion proteins, today announced that its 2011 Annual General Meeting of the Shareholders will be held on Thursday, June 9, 2011 at 9:00 a.m. PT at the offices of Fasken Martineau at 2900 - 550 Burrard Street in Vancouver, British Columbia.

Due to the ongoing negotiations and potential for full scale strike between Canada Post and the Canadian Union of Postal Workers, shareholders should also be aware of non-mail voting options.  Proxy forms also permit 24 hour a day voting by telephone and internet.

• To vote by telephone or the Internet, you will need to provide your CONTROL NUMBER listed on your proxy form. 
  
  
• To vote by phone, dial toll free from a touch tone phone: 1-866-732-VOTE (8683).
  
  
• To vote on the internet, go to www.investorvote.com.
  
  
• If you vote by telephone or the Internet, DO NOT mail back your proxy form.
  
  
• Voting by mail may be the only method for securities held in the name of a corporation or securities being voted on behalf of another individual.
  
  
• Voting by mail or by Internet are the only methods by which a holder may appoint a person as proxy holder other than the Management nominees named on the proxy form.

About Protox
Protox Therapeutics is a leader in advancing novel, receptor targeted therapeutic fusion proteins. Two drug candidates derived from the company's INxin™ and PORxin™ platforms are in clinical development.  Protox's lead program, PRX302 (PORxin), achieved positive results from its Phase 2b placebo controlled trial called TRIUMPH, to treat benign prostatic hyperplasia (BPH or enlarged prostate). Protox has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. PRX321 (INxin) is being developed for the treatment of various cancers and has received Fast Track Designation and Orphan Drug Status from the US FDA and EMEA for the treatment of primary brain cancer. For more information, please visit www.protoxtherapuetics.com.

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Protox' current beliefs as well as assumptions made by and information currently available to Protox and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.  Due to risks and uncertainties, including the risks and uncertainties identified by Protox in its public securities filings; actual events may differ materially from current expectations. Protox disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Protox Therapeutics Inc.

For further information: